



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,562	10/09/2001	Toshikazu Yoshikawa	4296-145-US	4594

7590 07/08/2003

Mathews Collins Shepherd & Gould  
100 Thanet Circle Suite 306  
Princeton, NJ 08540

EXAMINER

FONDA, KATHLEEN KAHLER

ART UNIT

PAPER NUMBER

1623

DATE MAILED: 07/08/2003

9

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/890,562	YOSHIKAWA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Kathleen Kahler Fonda, Ph.D.	1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) Responsive to communication(s) filed on 24 June 2003.

2a) This action is **FINAL**.                            2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) Claim(s) 5-10 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 5-10 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_

4) Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_

5) Notice of Informal Patent Application (PTO-152)

6) Other: \_\_\_\_\_

Art Unit: 1623

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Any rejection or objection made in a prior Office action and not expressly repeated herein is withdrawn in view of Applicant's arguments and/or amendments.

Claim 5 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Specifically, no support is seen for the amendment which replaces "the hydrogen atom of the hydroxyl group" with --the hydrogen atom at all or independently of each other at any of the hydroxyl groups--. Applicant does not point out where support for this amendment can be found, and the Examiner can find none.

Claims 5-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point

Art Unit: 1623

out and distinctly claim the subject matter which Applicant regards as the invention.

The scope of claim 5 as amended is unclear because there is an apparent mismatch between the preamble and the body of the claim. The preamble recites "treating arteriosclerosis" but the body of the claim does not require that the subject who receives the administration of the agent be afflicted with arteriosclerosis. Thus the claim is indefinite. Claims 6-10 are included in this rejection because they depend from claim 5 and do not rectify the indefiniteness. Applicant is advised that this rejection could be overcome by amending claim 5 to recite that the subject is in need of the treatment.

Claims 5-10 are again rejected, as set forth in the Office action of 12-18-02, under 35 U.S.C. 103(a) as being unpatentable over MURASE et al. (A1) in view of CYNSHI et al. (B3).

Applicant's claims have been amended to recite a method for treating arteriosclerosis by administering a chromanol glucoside.

Applicant's arguments filed 06-24-03 have been fully considered but they are not persuasive. Applicant argues that many factors are important in the development and possible treatment of arteriosclerosis, and that despite the *in vitro*

Art Unit: 1623

testing reported in the prior art to MURASE, the references do not provide a basis for believing that administration of a chromanol glucoside would be effective *in vivo* for treatment of arteriosclerosis. The Examiner does not agree. As stated in the previous Office action, both references relied on by the Examiner suggest *in vivo* use of antioxidants for treatment of arteriosclerosis, and MURASE provides data to demonstrate *in vitro* that the agents of the claims are antioxidants. As Applicant is aware, absolute predictability is not required in order for a *prima facie* case of obviousness to be established. All that is necessary is a reasonable expectation of success. The Examiner continues to maintain that there would have been a reasonable expectation of success, because MURASE had taught that the agents of the claims were antioxidants *in vitro*, and both MURASE and CYNSHI had suggested that antioxidants could be used to treat arteriosclerosis or slow its progression. The suggestion of CYNSHI mentions a number of antioxidants and so shows the generality of the Examiner's conclusion, while MURASE addresses the antioxidant activity and potential therapeutic utility (see column 1, lines 14-23 and 62-67) of chromanol glucoside specifically.

Art Unit: 1623

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Papers relating to this application may be submitted to Technology Center 1600 by facsimile transmission. The number of the fax machine for official papers in Technology Center 1600 is (703) 308-4556. Any document submitted by facsimile transmission will be considered an official communication unless

Art Unit: 1623

the cover sheet clearly indicates that it is an informal communication.

INTERNET INFORMATION: Secure and confidential access to patent application status information is now available; see <http://www.uspto.gov/ebc/index.html> for more information. Also, <http://www.uspto.gov/web/offices/ac/comp/fin/clonedefault.htm> may be used to pay patent maintenance fees, pay non-filing application fees, and maintain USPTO deposit accounts.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Kathleen Kahler Fonda, at telephone number (703) 308-1620. Examiner Fonda can generally be reached Monday through Friday from 7:30 a.m. until 4:00 p.m. If the Examiner cannot be reached, questions may be addressed to Supervisory Patent Examiner James O. Wilson at (703) 308-4624. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-1235.



Kathleen Kahler Fonda, Ph.D., J.D.  
Primary Examiner  
Art Unit 1623